US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

China SXT Pharmaceuticals, Inc. - Class A Ordinary Shares (NQ:SXTC)

0.1487 -0.1948 (-56.71%)
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about China SXT Pharmaceuticals, Inc. - Class A Ordinary Shares

News headline image
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
From China SXT Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering
From China SXT Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
China SXT Pharmaceuticals, Inc. Announces Share Re-classification
From China SXT Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
From China SXT Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN
From China SXT Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering
From China SXT Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Market Signals Flash Bullish for RDZN, NVVE, JTAI, SXTC, UAVS – Momentum Pointing Higher
Via AB Newswire
Topics Artificial Intelligence Fraud
News headline image
Roadzen (NASDAQ: RDZN) Strengthens Platform with Strategic VehicleCare Acquisition – Market Signals Point to New Highs Alongside NVVE, JTAI, SXTC, UAVS
Via AB Newswire
Topics Artificial Intelligence Fraud
News headline image
CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENT
From China SXT Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency
From China SXT Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
From China SXT Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
From China SXT Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq’s Minimum Bid Price Rule
From China SXT Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
China SXT Pharmaceuticals, Inc. Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule
From China SXT Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
From China SXT Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC).
NEW YORK, NY / ACCESSWIRE / January 20, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China... 
From Aegis Capital Corp.
Via AccessWire